The gap between optimal management of advanced NSCLC and current clinical practice is widening as many oncologists remain unaware of how best to apply new and emerging clinical evidence into their clinical practice. Oncologists and other cancer professionals have an opportunity to prolong life and improve the quality of life in selected patients with advanced NSCLC by more thoroughly defining molecular subsets of advanced NSCLC and more fully integrating the use of targeted therapies into treatment regimens. This fourth and final i-Newsletter issue in this series focuses on promising emerging oncogenes and targeted therapies.
Oncologists, nurse practitioners, physician assistants, nurses, and other health care professionals interested or involved in the treatment of NSCLC.
This activity is sponsored by Albert Einstein College of Medicine of Yeshiva University.
This activity is supported by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Astellas Pharma Global Development, Inc.
For full program information, please click on “BEGIN” button and follow the next click-through to reach this program site. Once you get to the “CMECorner” site description page, you will review program information, program content, take the test, and receive credit.
If you have any questions relating to the accreditation of this activity, please contact:
Center for Continuing Medical Education
Bronx, NY 10467
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.